Kymera Therapeutics to present KT-621 at European medical congresses
Kymera Therapeutics announced presentations on KT-621, an oral first-in-class STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology congresses.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.